A Moghaddam1, A Sperl1, R Heller1, H J Gerner1, B Biglari2. 1. Department of Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, HTRG-Heidelberg Trauma Research Group, Heidelberg University Hospital, Heidelberg, Germany. 2. Department of Paraplegiology, Berufsgenossenschaftliche Unfallklinik Ludwigshafen, Ludwigshafen, Germany.
Abstract
STUDY DESIGN: A prospective observational study reporting correlation between sCD95L (serum cluster of differentiation 95 ligand) serum levels and remission after traumatic spinal cord injury (SCI). OBJECTIVES: To describe the correlation between sCD95L serum levels and remission after traumatic SCI in a human protocol compared with animal studies. SETTING: Rhineland-Palatinate (Rheinland-Pfalz), Germany. METHODS: We included 45 patients with traumatic SCI. According to their neurological outcome, patients were divided into two groups, patients with (G1, n=26) and without (G2, n=19) remission. Blood was collected on post-admission and according to a fixed scheme, that is, after 4, 9, 12 h, 1, 3 days and 1, 2, 4, 8, 12 weeks. RESULTS: By comparing G1 with G2, we found a correlation between neurological remission and sCD95L serum concentrations. Consistently elevated levels of sCD95L in G1 between 9 h and 1 month after injury show significantly differing values 7 days after injury. This indicates a correlation between patients with clinically documented neurological remission and elevated sCD95L serum concentrations. CONCLUSIONS: In opposite to animal studies, our patients with neurological remission show on average higher levels of sCD95L compared with patients without. Therefore, spinal cord-injured patients would probably not profit from neutralizing CD95L. Our results present that the transfer of findings from animal studies to humans must always be considered critically. We were able to show that peripheral serum cytokine expression is suitable to state processes after SCI in humans.
STUDY DESIGN: A prospective observational study reporting correlation between sCD95L (serum cluster of differentiation 95 ligand) serum levels and remission after traumatic spinal cord injury (SCI). OBJECTIVES: To describe the correlation between sCD95L serum levels and remission after traumatic SCI in a human protocol compared with animal studies. SETTING: Rhineland-Palatinate (Rheinland-Pfalz), Germany. METHODS: We included 45 patients with traumatic SCI. According to their neurological outcome, patients were divided into two groups, patients with (G1, n=26) and without (G2, n=19) remission. Blood was collected on post-admission and according to a fixed scheme, that is, after 4, 9, 12 h, 1, 3 days and 1, 2, 4, 8, 12 weeks. RESULTS: By comparing G1 with G2, we found a correlation between neurological remission and sCD95L serum concentrations. Consistently elevated levels of sCD95L in G1 between 9 h and 1 month after injury show significantly differing values 7 days after injury. This indicates a correlation between patients with clinically documented neurological remission and elevated sCD95L serum concentrations. CONCLUSIONS: In opposite to animal studies, our patients with neurological remission show on average higher levels of sCD95L compared with patients without. Therefore, spinal cord-injured patients would probably not profit from neutralizing CD95L. Our results present that the transfer of findings from animal studies to humans must always be considered critically. We were able to show that peripheral serum cytokine expression is suitable to state processes after SCI in humans.
Authors: C Zuliani; S Kleber; S Klussmann; T Wenger; M Kenzelmann; N Schreglmann; A Martinez; J A del Rio; E Soriano; P Vodrazka; R Kuner; H-J Groene; I Herr; P H Krammer; A Martin-Villalba Journal: Cell Death Differ Date: 2006-01 Impact factor: 15.828
Authors: Bahram Biglari; Axel Büchler; Tyler Swing; Christopher Child; Elisabeth Biehl; Tim Reitzel; Tom Bruckner; Thomas Ferbert; Sebastian Korff; Harald Rief; Hans-Jürgen Gerner; Arash Moghaddam Journal: J Int Med Res Date: 2015-01-19 Impact factor: 1.671
Authors: J L Marsh; Theddy F Slongo; Julie Agel; J Scott Broderick; William Creevey; Thomas A DeCoster; Laura Prokuski; Michael S Sirkin; Bruce Ziran; Brad Henley; Laurent Audigé Journal: J Orthop Trauma Date: 2007 Nov-Dec Impact factor: 2.512
Authors: Wan Huang; Yoram Vodovotz; Mary B Kusturiss; Derek Barclay; Karen Greenwald; Michael L Boninger; Paul M Coen; David Brienza; Gwendolyn Sowa Journal: PM R Date: 2013-10-17 Impact factor: 2.298
Authors: B Biglari; A Büchler; T Swing; E Biehl; H J Roth; T Bruckner; G Schmidmaier; T Ferbert; H J Gerner; A Moghaddam Journal: Spinal Cord Date: 2012-11-27 Impact factor: 2.772
Authors: Arash Moghaddam; Christopher Child; Thomas Bruckner; Hans Jürgen Gerner; Volker Daniel; Bahram Biglari Journal: Int J Mol Sci Date: 2015-04-09 Impact factor: 5.923
Authors: R A Heller; T F Raven; T Swing; K Kunzmann; V Daniel; P Haubruck; M Akbar; P A Grützner; G Schmidmaier; B Biglari; A Moghaddam Journal: Spinal Cord Date: 2017-06-20 Impact factor: 2.772
Authors: Patrick Haubruck; Raban Heller; Michael C Tanner; Volker Daniel; Gerhard Schmidmaier; Farhoud Bolourchi; Arash Moghaddam; Christian Fischer Journal: Diagnostics (Basel) Date: 2018-08-24